TauRx

TauRx is a pioneering force in pharmaceutical manufacturing, dedicated to addressing the critical challenges posed by Alzheimer's disease and other neurodegenerative brain disorders. Through innovative research and a groundbreaking approach, TauRx is committed to discovering, developing, and commercializing cutting-edge products for the diagnosis, treatment, and potential cure of these debilitating conditions.

Located at its primary address at 395 King Street, Aberdeen, GB, TauRx leverages a strong research team and collaborative relationships with academic institutions worldwide to focus on the tau pathway, a key factor in neurodegeneration. TauRx's novel tau aggregation inhibitors (TAIs) are designed to target the formation of tau protein 'tangles' in the brain, showing promising pharmacological effects in early trials for individuals with mild to moderate Alzheimer's disease. The experimental drug is currently under development for the treatment and prevention of Alzheimer’s disease.

In close collaboration with Genting TauRx Diagnostics Ltd (GTD), TauRx is also actively involved in developing innovative diagnostic tools and blood tests for dementia. These advancements aim to transform the treatment pathway for those affected, ensuring efficient and early diagnosis, and improving access to essential treatment and care. TauRx is dedicated to advancing the field of neurodegenerative disease research and making a meaningful impact on the lives of patients and their families. The company's management is currently completing additional details, so stay tuned for more information.

We invite the manager of TauRx to create a customized and exclusive company showcase and product listing on our platform.